Tocilizumab for COVID-19: A systematic review and meta-analysis of randomized controlled trials
The effective treatment modalities for severe coronavirus disease 2019 (COVID-19) are needed. As the primary cause of mortality is a hyperinflammatory state, the interleukin-6 antagonist tocilizumab has been used in multiple clinical studies. We conducted this systematic review and meta-analysis to...
Na minha lista:
| Principais autores: | , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
PAGEPress Publications
2022-02-01
|
| Colecção: | Monaldi Archives for Chest Disease |
| Assuntos: | |
| Acesso em linha: | https://www.monaldi-archives.org/index.php/macd/article/view/2136 |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|